Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design
- 18 October 2018
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (20)
Abstract
HIV eradication studies have focused on developing latency-reversing agents (LRAs). However, it is not understood how the rate of latent reservoir reduction is affected by different steps in the process of latency reversal. Furthermore, as current LRAs are host-directed, LRA treatment is likely to be intermittent to avoid host toxicities. Few careful studies of the serial effects of pulsatile LRA treatment have yet been done. This lack of clarity makes it difficult to evaluate the efficacy of candidate LRAs or predict long-term treatment outcomes. We constructed a mathematical model that describes the dynamics of latently infected cells under LRA treatment. Model analysis showed that, in addition to increasing the immune recognition and clearance of infected cells, the duration of HIV antigen expression (i.e., the period of vulnerability) plays an important role in determining the efficacy of LRAs, especially if effective clearance is achieved. Patients may benefit from pulsatile LRA exposures compared with continuous LRA exposures if the period of vulnerability is long and the clearance rate is high, both in the presence and absence of an LRA. Overall, the model framework serves as a useful tool to evaluate the efficacy and the rational design of LRAs and combination strategies.Keywords
Funding Information
- NIH, DOE and NSF (DE-AC52-06NA25396,R01-OD011095,R01-AI028433,P01-AI131365,UM1AI126619,P30 AI50410,DMS-1714654)
This publication has 77 references indexed in Scilit:
- Quantifying T lymphocyte turnoverJournal of Theoretical Biology, 2013
- Antiretroviral dynamics determines HIV evolution and predicts therapy outcomeNature Medicine, 2012
- Towards an HIV cure: a global scientific strategyNature Reviews Immunology, 2012
- A quantitative basis for antiretroviral therapy for HIV-1 infectionNature Medicine, 2012
- Dose–response curve slope is a missing dimension in the analysis of HIV-1 drug resistanceProceedings of the National Academy of Sciences, 2011
- HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferationNature Medicine, 2009
- The Challenge of Finding a Cure for HIV InfectionScience, 2009
- Modelling viral and immune system dynamicsNature Reviews Immunology, 2002
- Decay characteristics of HIV-1-infected compartments during combination therapyNature, 1997
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995